ash impact series: ruben mesa, md - examining the current role of ruxolitinib in myelofibrosis
Published 7 years ago • 572 plays • Length 3:13
Download video MP4
Download video MP3
Similar videos
-
6:07
ruben a. mesa, md: treating myelofibrosis after ruxolitinib “failure”
-
5:33
ruben mesa, md: momelotinib non-inferior to ruxolitinib in myelofibrosis
-
6:36
2022 ash conference - dr. ruben mesa, md
-
30:30
dr ruben mesa-myelofibrosis and advancing mpns: current and future approaches
-
59:36
control myelofibrosis
-
2:02:32
all hematology review (internal medicine)
-
13:58
myelofibrosis disease overview and treatment options
-
1:50
2017 ash mhm: focus on mpn – ruben mesa, md
-
2:55
ruben mesa, md: ruxolitinib as a myelofibrosis treatment
-
7:28
ash 2019 mpn updates, ruben mesa, md.
-
17:41
for myelofibrosis patients: the latest on promising treatments from top specialist | dr. ruben mesa
-
1:15
ash meeting on hematologic malignancies: ruben mesa, md
-
1:10
dr. ruben mesa on comfort-1 for myelofibrosis
-
51:55
ruben mesa, md, ut health san antonio
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
3:30
ash impact series: hetty carraway, md - treatment of patients with high grade mds
-
1:52
ruben mesa, md on myelofibrosis (full interview)
-
1:25
highlights on myelofibrosis from ash
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:37
dr ruben mesa outlines the quality of life impact of myelofibrosis
-
0:33
ruben mesa, md discusses pathophysiology and treatment of myelofibrosis
Clip.africa.com - Privacy-policy